CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	9 Months Ended
	Oct. 01, 2011	Oct. 02, 2010
Cash flows from continuing operating activities:
Income from continuing operations	$ 57,230	$ 46,381
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	12,818	12,309
Investment premium amortization, net	2,935	3,795
Loss on extinguishment of senior subordinated convertible notes		99
Non-cash interest income and other	378	687
Non-cash interest expense	2,815	7,152
Write-down on investment		2,057
Tax benefit related to stock options	1,348	10,343
Share-based compensation expense	11,732	9,624
Excess tax benefits from share-based compensation	(1,397)	(9,458)
Loss on disposal of assets	26	529
Change in deferred taxes, net	(4,055)	(4,027)
Changes in assets and liabilities, net of acquisition of Levitronix Medical:
Receivables	4,268	(3,080)
Inventories	779	(15,939)
Prepaid expenses and other assets	(271)	(277)
Accrued compensation and other accrued liabilities	(4,490)	10,310
Accounts payable	(1,021)	4,718
Income taxes, net	4,018	(13,851)
Net cash provided by continuing operating activities	87,113	61,372
Cash flows from continuing investing activities:
Purchases of available-for-sale investments	(236,399)	(398,874)
Sales and maturities of available-for-sale investments	476,264	338,613
Acquisition of Levitronix Medical, net of cash acquired	(109,974)
Loan collections		2,756
Purchases of property, plant and equipment, net	(5,724)	(2,848)
Purchases of patents		(1,414)
Net cash provided by (used in) continuing investing activities	124,167	(61,767)
Cash flows from continuing financing activities:
Excess tax benefits from share-based compensation	1,397	9,458
Proceeds from stock option exercises	10,212	22,035
Proceeds from stock issued under the employee stock purchase plan	1,886	1,884
Repurchase and retirement of common shares	(53,725)	(4,698)
Extinguishment of senior subordinated convertible notes	(164,429)	(5,358)
Net cash (used in) provided by continuing financing activities	(204,659)	23,321
Effect of exchange rate changes on cash and cash equivalents	(568)	(4)
Net cash provided by continuing operations	6,053	22,922
Cash flows from discontinued operations:
Net cash (used in) provided by operating activities	(165)	2,488
Net cash used in investing activities		(2,488)
Net cash used in discontinued operations	(165)
Net increase in cash and cash equivalents	5,888	22,922
Net cash and cash equivalents at beginning of period	56,887	27,787
Net cash and cash equivalents at end of period	62,775	50,709
Supplemental disclosure of consolidated cash flow information:
Cash paid for taxes	28,006	30,494
Cash paid for interest	1,679	1,707
Supplemental disclosure of consolidated non-cash investing and financing activities:
Transfers of equipment from inventory	1,689	3,493
Purchases of property, plant and equipment through accounts payable and accrued liabilities	355	221
Issuance of shares for extinguishment of senior subordinated convertible notes	82,711
Acquisition related earn-out obligations included in accrued liabilities	580
Contingent earn-out obligations included in contingent liabilities	$ 22,990